Accessibility Menu
GenSight Biologics logo

GenSight Biologics

(OTC) GSGTF

Current Price$0.19
Market Cap$44.57M
Since IPO (2018)-97%
5 Year-98%
1 Year-21%
1 Month+0%

GenSight Biologics Financials at a Glance

Market Cap

$44.57M

Revenue (TTM)

€1.50M

Net Income (TTM)

-€26.04M

EPS (TTM)

-$0.09

P/E Ratio

-2.10

Dividend

$0.00

Beta (Volatility)

-124.74 (Low)

Price

$0.19

Volume

1

Open

$0.19

Previous Close

$0.19

Daily Range

$0.19 - $0.19

52-Week Range

$0.19 - $0.24

Estimated Earnings Date

Jul 23, 2026

GSGTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GenSight Biologics

Industry

Biotechnology

Employees

13

CEO

Laurence Rodriguez

Headquarters

Paris, 75012, FR

GSGTF Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-11684%

Net Income Margin

-12036%

Return on Equity

0%

Return on Capital

3%

Return on Assets

-1%

Earnings Yield

-47.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$44.57M

Shares Outstanding

234.47M

Volume

1

Avg. Volume

0.016

Financials (TTM)

Gross Profit

€1.00K

Operating Income

-€11.70M

EBITDA

-€11.24M

Operating Cash Flow

-€9.17M

Capital Expenditure

€9.17M

Free Cash Flow

€0.00

Cash & ST Invst.

€2.41M

Total Debt

€12.86M

GenSight Biologics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

-€47.00K

+83.4%

Gross Profit

-€47.00K

+98.0%

Gross Margin

100.00%

N/A

Market Cap

$44.57M

N/A

Market Cap/Employee

$2.79M

N/A

Employees

16

N/A

Net Income

-€5.07M

+64.5%

EBITDA

-€4.53M

+60.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€2.41M

+13.1%

Total Debt

€12.86M

-30.2%

Accounts Receivable

€0.00

-100.0%

Inventory

€0.00

N/A

Long Term Debt

€9.22M

+779.5%

Short Term Debt

€3.64M

-79.1%

Return on Assets

-1.46%

N/A

Return on Invested Capital

2.65%

N/A

Free Cash Flow

€0.00

+100.0%

Operating Cash Flow

-€6.49M

+23.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOVNFBioInvent International AB (publ)
$3.29+0.00%
VBIZFViva Biotech Holdings
$0.16+8.73%
SOLTFNxera Pharma Co., Ltd.
$6.19+0.00%
AGYTFAllergy Therapeutics plc
$0.13+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98+0.02%
NOKNokia
$14.80+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.59+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$77.52+0.02%

Questions About GSGTF

What is the current price of GenSight Biologics?

GenSight Biologics is trading at $0.19 per share.

What is the 52-week range for GenSight Biologics?

Over the past 52 weeks, GenSight Biologics has traded between $0.19 and $0.24.

How much debt does GenSight Biologics have?

As of the most recent reporting period, GenSight Biologics reported total debt of €15.11M.

How much cash does GenSight Biologics have on hand?

GenSight Biologics reported €2.84M in cash and cash equivalents in its most recent financial results.

What is GenSight Biologics’s dividend yield?

GenSight Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.